Reporter brief
Pilot RCT of senolytics in childhood cancer survivors shows design but lacks efficacy data
What happened
SEN-SURVIVORS is an open-label pilot trial testing two senolytic regimens (dasatinib plus quercetin, and fisetin alone) in adult survivors of childhood cancer. The study aimed to measure changes in walking speed and blood senescent cell markers (p16^INK4a) at 60 days, with extended follow-up at 150 days. The abstract describes the study design and objectives but reports no results, efficacy measures, or outcomes.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Adult survivors of childhood cancer
- Design
- Rct
- Sample
- —
- Journal
- St. Jude Children's Research Hospital
- Published
- Sep 30, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.